Nyrada’s PCSK9 Inhibitor Evaluated In Novel Model Of Atherosclerosis

July 20, 2022 Nyrada Inc. (ASX:NYR) released an announcement headed “Nyrada’s PCSK9 Inhibitor Evaluated in Novel Model of Atherosclerosis”. We believe that the market has missed the significance of this important news. In a bio-engineered model of atherosclerosis developed in a laboratory by researchers at Duke University (US), Nyrada’s PCSK9 inhibitor has been shown to block the early stages of plaque progression including the prevention of adhesion to artery walls as well as the suppression of inflammatory cytokines, both of which are important in the progression of cardiovascular disease. The model is based on novel human tissue-engineered blood vessels (TEBVS)  that replicate naturally occurring blood vessels outside the body.

The primary objective of the study was to determine if PCSK9 inhibitors reduce inflammation in vascular cells in the early phases of atherosclerosis. The results were presented at the North American Vascular Biology Organisation’s (NAVBO) 2022 Vasculata conference in North Carolina on 19th of July 2022.

Nyrada Chief Scientific Officer, Dr Benny Evison, was excited by the opportunity to test Nyrada’s PCSK9 inhibitor technology in a model which allowed its function to be fully explored beyond its known role in regulating LDL-cholesterol metabolism in the liver.

Dr Evison said “This research is important because it advances the understanding of PCSK9 and its function in the body. It also broadens our understanding of the mode of action of Nyrada’s drug. Given that atherosclerosis plaque build-up is a major cause of cardiovascular disease, the opportunity to therapeutically target this disease in its early stages is highly encouraging.”

Canary Capital believes that this research is important because it highlights the potential for Nyrada’s PCSK9 inhibitor to play a dual role in helping to reduce the instances of cardiovascular disease by regulating LDL- cholesterol metabolism as well as the potential to reduce the build-up of plaque in the arteries of patients who are susceptible to the development of cardiovascular disease.

Following is a link to information about the model which was published in Nature Communications: